Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 BioLineRxMarker TherapeuticsLumos PharmaInflaRxAssertio
SymbolNASDAQ:BLRXNASDAQ:MRKRNASDAQ:LUMONASDAQ:IFRXNASDAQ:ASRT
Price Information
Current Price$2.67$2.09$11.93$3.70$0.53
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.61.51.71.41.6
Analysis Score3.53.43.53.33.5
Community Score3.12.53.42.42.6
Dividend Score0.00.00.00.00.0
Ownership Score0.01.70.80.00.8
Earnings & Valuation Score1.30.00.61.31.3
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$19.00$8.67$30.43$11.57$3.50
% Upside from Price Target611.61% upside314.67% upside155.06% upside212.74% upside559.88% upside
Trade Information
Market Cap$113.77 million$165.74 million$99.40 million$159.94 million$92.00 million
Beta2.081.271.690.561.68
Average Volume1,784,0723,119,27460,150403,44815,911,063
Sales & Book Value
Annual RevenueN/A$210,000.00$940,000.00N/A$229.50 million
Price / SalesN/A789.25105.75N/A0.40
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$4.46 per share$0.96 per share$19.03 per share$4.62 per share$0.72 per share
Price / BookN/A2.180.63N/A0.74
Profitability
Net Income$-25,450,000.00$-21,430,000.00$-42,990,000.00$-59,650,000.00$-217,200,000.00
EPS($2.55)($0.47)($9.27)($2.29)($3.07)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-2,053.30%N/A-145.15%
Return on Equity (ROE)-96.27%-68.00%-10.58%-39.58%-259.36%
Return on Assets (ROA)-55.87%-54.26%-7.83%-35.01%-55.13%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.14%N/AN/AN/A1.02%
Current Ratio2.05%5.03%19.41%8.65%0.80%
Quick Ratio2.04%5.03%19.40%8.65%0.69%
Ownership Information
Institutional Ownership Percentage17.46%29.42%43.79%13.71%39.95%
Insider Ownership Percentage1.10%30.90%15.90%N/A2.69%
Miscellaneous
Employees3828284327
Shares Outstanding42.61 million79.30 million8.33 million43.23 million173.45 million
Next Earnings Date5/19/2021 (Estimated)5/10/2021 (Estimated)5/27/2021 (Estimated)5/20/2021 (Estimated)5/10/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableNot OptionableOptionable
SourceHeadline
Is Assertio Holdings Inc (ASRT) a Leader in the Drug Manufacturers - Specialty & Generic Industry? - InvestorsObserverIs Assertio Holdings Inc (ASRT) a Leader in the Drug Manufacturers - Specialty & Generic Industry? - InvestorsObserver
investorsobserver.com - April 15 at 5:20 PM
30 Stocks Moving In Thursdays Mid-Day Session - Benzinga30 Stocks Moving In Thursday's Mid-Day Session - Benzinga
benzinga.com - April 15 at 12:19 PM
22 Stocks Moving in Thursdays Pre-Market Session - Benzinga22 Stocks Moving in Thursday's Pre-Market Session - Benzinga
benzinga.com - April 15 at 7:17 AM
Why Assertio Holdings Inc (ASR) stock is rallying on Thursday’s pre-market? - Market GlobalistWhy Assertio Holdings Inc (ASR) stock is rallying on Thursday’s pre-market? - Market Globalist
marketglobalist.com - April 15 at 7:17 AM
Assetio (ASRT) Stock Has Lost Almost All Its This Year Gain – Own Snap - Own SnapAssetio (ASRT) Stock Has Lost Almost All Its This Year Gain – Own Snap - Own Snap
ownsnap.com - April 14 at 1:00 PM
Assertio Holdings, Inc. (NASDAQ:ASRT) Forecast to gain 181.82% to hit Consensus price targetAssertio Holdings, Inc. (NASDAQ:ASRT) Forecast to gain 181.82% to hit Consensus price target
marketingsentinel.com - April 14 at 1:39 AM
Assertio (NASDAQ:ASRT) Upgraded to "Buy" at GabelliAssertio (NASDAQ:ASRT) Upgraded to "Buy" at Gabelli
americanbankingnews.com - April 13 at 7:10 PM
Airline Stocks - Assertio Holdings Inc. (ASRT), JetBlue Airways Corporation (JBLU) have attractive valuations – BOV News - Fintech ZoomAirline Stocks - Assertio Holdings Inc. (ASRT), JetBlue Airways Corporation (JBLU) have attractive valuations – BOV News - Fintech Zoom
fintechzoom.com - April 13 at 3:32 PM
Wall Street Roundup: Bullish & Bearish Calls Of The Day - Yahoo FinanceWall Street Roundup: Bullish & Bearish Calls Of The Day - Yahoo Finance
finance.yahoo.com - April 12 at 11:07 PM
Benzingas Top Ratings Upgrades, Downgrades For April 9, 2021 - BenzingaBenzinga's Top Ratings Upgrades, Downgrades For April 9, 2021 - Benzinga
benzinga.com - April 11 at 9:18 AM
Trading Penny Stocks? 5 You Can Buy Under $1 On Robinhood Right Now - Penny StocksTrading Penny Stocks? 5 You Can Buy Under $1 On Robinhood Right Now - Penny Stocks
pennystocks.com - April 9 at 9:46 AM
Global Gabapentin Market 2021 Top Manufactures – Pfizer, Intas, Assertio Therapeutics, Mylan, Arbor Pharma, TEVA, Sun Pharmaceutical – FLA News - FLA NewsGlobal Gabapentin Market 2021 Top Manufactures – Pfizer, Intas, Assertio Therapeutics, Mylan, Arbor Pharma, TEVA, Sun Pharmaceutical – FLA News - FLA News
flanewsonline.com - April 8 at 8:16 AM
Analysts Conflicted on These Healthcare Names: Assertio Therapeutics (NASDAQ: ASRT), Frequency Therapeutics (NASDAQ: FREQ) and Cardiol Therapeutics (Other OTC: CRTPF) - Analyst RatingsAnalysts Conflicted on These Healthcare Names: Assertio Therapeutics (NASDAQ: ASRT), Frequency Therapeutics (NASDAQ: FREQ) and Cardiol Therapeutics (Other OTC: CRTPF) - Analyst Ratings
analystratings.com - April 6 at 10:43 AM
Assertio (NASDAQ:ASRT) Earns "Hold" Rating from GabelliAssertio (NASDAQ:ASRT) Earns "Hold" Rating from Gabelli
americanbankingnews.com - April 6 at 8:16 AM
Assertio (ASRT) Surges 60% So Far This Year: What Next? – Own Snap - Own SnapAssertio (ASRT) Surges 60% So Far This Year: What Next? – Own Snap - Own Snap
ownsnap.com - April 5 at 7:24 AM
Assertio Holdings, Inc. (NASDAQ:ASRT)’s stock falls -1.99%, but it may be worth investing inAssertio Holdings, Inc. (NASDAQ:ASRT)’s stock falls -1.99%, but it may be worth investing in
stocksregister.com - March 29 at 9:57 AM
Hot Penny Stocks To Watch Before April 2021 | FinancialContent Business Page - Financial ContentHot Penny Stocks To Watch Before April 2021 | FinancialContent Business Page - Financial Content
markets.financialcontent.com - March 26 at 5:50 PM
Assertio Holdings, Inc. (NASDAQ:ASRT) Down Almost -25.27% in 1 Month, But Long Term Looking GoodAssertio Holdings, Inc. (NASDAQ:ASRT) Down Almost -25.27% in 1 Month, But Long Term Looking Good
marketingsentinel.com - March 26 at 12:49 PM
InvestorNewsBreaks – Assertio Holdings Inc. (NASDAQ: ASRT) Closes $14M, $34.3M Registered Direct Offerings - StreetInsider.comInvestorNewsBreaks – Assertio Holdings Inc. (NASDAQ: ASRT) Closes $14M, $34.3M Registered Direct Offerings - StreetInsider.com
streetinsider.com - March 16 at 6:35 PM
Implied Volatility Surging for Assertio Holdings (ASRT) Stock Options - Yahoo FinanceImplied Volatility Surging for Assertio Holdings (ASRT) Stock Options - Yahoo Finance
finance.yahoo.com - March 15 at 5:31 PM
Implied Volatility Surging for Assertio Holdings (ASRT) Stock Options - NasdaqImplied Volatility Surging for Assertio Holdings (ASRT) Stock Options - Nasdaq
nasdaq.com - March 15 at 12:30 PM
3 Penny Stocks To Buy Under $1 On Webull, Fidelity & Others Right Now - StreetInsider.com3 Penny Stocks To Buy Under $1 On Webull, Fidelity & Others Right Now - StreetInsider.com
streetinsider.com - March 14 at 9:27 PM
Assertio reports decline in sales - Chicago Daily HeraldAssertio reports decline in sales - Chicago Daily Herald
dailyherald.com - March 13 at 1:18 AM
Assertio Holdings, Inc. (ASRT) CEO Dan Peisert on Q4 2020 Results - Earnings Call Transcript - Seeking AlphaAssertio Holdings, Inc. (ASRT) CEO Dan Peisert on Q4 2020 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 12 at 3:17 PM
Health Care Sector Update for 03/12/2021: ALT, CAPR, ASRT, IYH, IBB, VHT - NasdaqHealth Care Sector Update for 03/12/2021: ALT, CAPR, ASRT, IYH, IBB, VHT - Nasdaq
nasdaq.com - March 12 at 10:15 AM
DateCompanyBrokerageAction
3/1/2021BioLineRxHC WainwrightLower Price Target
8/7/2020BioLineRxMaxim GroupReiterated Rating
3/13/2020BioLineRxOppenheimerLower Price Target
3/31/2021Marker TherapeuticsPiper SandlerInitiated Coverage
3/24/2021Marker TherapeuticsCantor FitzgeraldInitiated Coverage
6/24/2020Marker TherapeuticsRoth CapitalReiterated Rating
6/24/2020Marker TherapeuticsJanney Montgomery ScottReiterated Rating
6/24/2020Marker TherapeuticsNomuraReiterated Rating
11/13/2019Marker TherapeuticsPiper Jaffray CompaniesLower Price Target
8/13/2019Marker TherapeuticsNomura SecuritiesReiterated Rating
3/29/2019Marker TherapeuticsWBB SecuritiesUpgrade
4/13/2021Lumos PharmaJonestradingInitiated Coverage
3/17/2021Lumos PharmaStifel NicolausUpgrade
4/16/2020Lumos PharmaJefferies Financial GroupInitiated Coverage
3/17/2021InflaRxGuggenheimUpgrade
11/6/2020InflaRxSVB LeerinkUpgrade
10/30/2020InflaRxLifesci CapitalReiterated Rating
9/14/2020InflaRxCi CapitalReiterated Rating
7/31/2020InflaRxRaymond JamesLower Price Target
6/16/2020InflaRxBTIG ResearchInitiated Coverage
5/21/2020InflaRxBMO Capital MarketsBoost Price Target
6/5/2019InflaRxCredit Suisse GroupDowngrade
6/5/2019InflaRxSunTrust BanksDowngrade
6/5/2019InflaRxRobert W. BairdDowngrade
4/13/2021AssertioGabelliUpgrade
9/18/2020AssertioG.ResearchReiterated Rating
6/3/2020AssertioBrookline Capital ManagementInitiated Coverage
5/16/2019AssertioMizuhoLower Price Target
(Data available from 4/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.